With 1.72 million shares changed hands, the volume of the stock remained heavier than its average volume of 1.32 million shares. During the session, the Biotechnology company that operates in wider Healthcare sector, reached to the highest price of $3.04 whereas the lowest price it dropped to was $2.88. The 52-week range on ATYR shows that it touched its highest point at $4.66 and its lowest point at $1.42 during that stretch. It currently has a 1-year price target of $18.55. Beta for the stock currently stands at 0.96.
Price Performance and Earnings:
Stock performance is one of the indicators that investors use to determine whether they will profit from a stock. The price performance of ATYR was down-trending over the past week, with a drop of -17.48%, but this was down by -12.73% over a month. Three-month performance dropped to -22.99% while six-month performance rose 62.71%. The stock gained 47.69% in the past year, while it has lost -20.44% so far this year. A look at the trailing 12-month EPS for ATYR yields -0.87 with Next year EPS estimates of -0.60. For the next quarter, that number is -0.19. This implies an EPS growth rate of 17.86% for this year and 15.32% for next year.
Float and Shares Shorts:
At present, 88.86 million ATYR shares are outstanding with a float of 86.00 million shares on hand for trading. On 2025-03-14, short shares totaled 6.92 million, which was 779.0 higher than short shares on 1739491200. In addition to Dr. Sanjay S. Shukla M.D., M.S. as the firm’s President, CEO & Director, Ms. Jill M. Broadfoot CPA serves as its Chief Financial Officer.
Institutional Ownership:
Through their ownership of 0.61916 of ATYR’s outstanding shares, institutional investors have minority control over the company.
An Overview of Recent Financials:
Understanding a company as a customer does not mean you will understand it as an investor. The wise investor uses quantitative research to analyze metrics such as revenue, net income, and earnings. In its fiscal quarter reported on 2024-12-31, ATYR reported revenue of $0.0 and operating income of -$15820000.0. The EBITDA in the recently reported quarter was -$15820000.0 and diluted EPS was $nan.
Analysts Ratings:
In the same way, a target price assigned to a stock can also reveal much about its potential. With ATYR analysts setting a high price target of 35.0 and a low target of 9.0, the average target price over the next 12 months is 18.55. Based on these targets, ATYR could surge 1115.28% to reach the target high and rise by 212.5% to reach the target low. Reaching the average price target will result in a growth of 544.1% from current levels.
EPS: Estimates vs Actual
It is also common to use earnings estimates to evaluate a firm’s growth potential and to determine trading strategy. Analysts have provided yearly estimates in a range of -$0.9009 being high and -$0.92092 being low. For ATYR, this leads to a yearly average estimate of -$0.91091. Based on analyst estimates, the high estimate for the next quarter is -$0.17 and the low estimate is -$0.25. The average estimate for the next quarter is thus -$0.19.
